TSLP and asthma: TAVO101 was a highly effective TSLP neutralizer and showed promising pharmacokinetic profiles in preclinical models, suggesting that it represents a promising candidate in the therapeutic arsenal for the treatment of asthma and other inflammatory diseases [50].